NCT02032524 - Avalglucosidase Alfa Extension Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 27, 2014

Primary Completion Date

December 12, 2022

Study Completion Date

December 12, 2022

Conditions

Glycogen Storage Disease Type II Pompe Disease

Interventions

DRUG

Avalglucosidase Alfa

Pharmaceutical form: lyophilized powder reconstituted for infusion Route of administration: intravenous

Trial Locations (17)

2100

Investigational Site Number 208001, København Ø

3000

Investigational Site Number 056001, Leuven

22030

Investigational Site Number 840003, Fairfax

27710

Investigational Site Number 840002, Durham

32209

Investigational Site Number 840010, Jacksonville

45219

Investigational Site Number 840011, Cincinnati

48149

Investigational Site Number 276002, Münster

55131

Investigational Site Number 276003, Mainz

63110

Investigational Site Number 840008, St Louis

75013

Investigational Site Number 250002, Paris

75390

Investigational Site Number 840009, Dallas

80336

Investigational Site Number 276001, München

85013

Investigational Site Number 840006, Phoenix

66160-7321

Investigational Site Number 840001, Kansas City

06000

Investigational Site Number 250003, Nice

3015 GJ

Investigational Site Number 528001, Rotterdam

NE1 4LP

Investigational Site Number 826003, Newcastle upon Tyne

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY